A kinase inhibitor called cabozantinib could be a viable therapy option for patients with metastatic, radioactive iodine-resistant thyroid cancer. In a recent trial tumors shrunk in 34 out of 35 patients who took the drug, and more than half of those patients saw the tumor size decrease by more than 30 percent.
from Diet and Weight Loss News -- ScienceDaily http://ift.tt/2EYUCqZ
No comments:
Post a Comment